IPF Competitive Intelligence: April 2026

Mar 1, 2026 - Apr 29, 2026

Five business development and financing events across the IPF therapeutic area: Avalyn Pharma's updated S-1/A filing targeting a $283 million IPO to advance inhaled pirfenidone (AP01) and inhaled nintedanib (AP02); Baseimmune's strategic entry into fibrosis with a preclinical IPF program; Cumberland Pharmaceuticals' $100 million asset sale to Apotex while retaining its ifetroban pipeline; Insilico Medicine's 2025 annual results highlighting $1.3 billion in new collaborations and Phase IIa proof-of-concept for its AI-discovered TNIK inhibitor Rentosertib; and Rein Therapeutics' public offering to fund operations through April 2027 with its RENEW Phase 2 trial for LTI-03 ongoing.